You are here: Industry Insights > fdc

News List

FDC launches Favipiravir oral suspension expresspharma
July 13, 2021
FDC has launched oral suspension of Favipiravir to treat mild to moderate cases of COVID-19 in the country.
There should be a change in SOP parameters for evaluating FDCs: Dr RK Sanghavi expresspharma
April 01, 2021
A sub-committee of DTAB has asked manufacturers of FDCs which were considered irrational by Prof Kokate Committee to present their perspective.
Glenmark launches Remogliflozin + Vildagliptin FDC in India to treat Type 2 diabetes expresspharma
December 30, 2020
The FDC will be marketed under two brand names Remo V and Remozen V priced at Rs 14 per tab and Rs 28 per day cost of therapy.
Industry experts disagree with NPPA’s remark on FDCs expresspharma
November 10, 2020
The National Pharmaceutical Pricing Authority’s (NPPA) recently raised concerns over the approval of FDCs.
FDC launches two favipiravir variants for COVID-19 treatment expresspharma
August 26, 2020
FDC announced the launch of two variants of favipiravir – PiFLU and Favenza – which will be used to treat mild to moderate cases of COVID-19 in India.
Kokate Committee releases list of 471 rational FDCs expresspharma
August 05, 2020
The Prof Kokate Committee has declared 471 fixed-dose combinations (FDC) related to vitamin, minerals and micronutrients as rational.
SC allows sale of Saridon, three other drugs financialexpress
September 19, 2018
The top court, however, did not grant any relief to the other medicines falling in the list of 328 FDC drugs which were banned by the Health Ministry by its September 7 notification
FDC seeks opportunities in untapped markets to boost revenue expressbpd
August 22, 2017
The company will be ready to supply current market requirement of IMS with spare capacity